Surface Oncology Inc
F:QSOA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Surface Oncology Inc
Research & Development
Surface Oncology Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Surface Oncology Inc
F:QSOA
|
Research & Development
-$59.8m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$8.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$6.8B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-16%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-13%
|
|
Surface Oncology Inc
Glance View
Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-04-19. The firm is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. The Company’s pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells through targeting CCR8 (SRF114). In addition, the Company has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562). Its novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
See Also
What is Surface Oncology Inc's Research & Development?
Research & Development
-59.8m
USD
Based on the financial report for Jun 30, 2023, Surface Oncology Inc's Research & Development amounts to -59.8m USD.
What is Surface Oncology Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-2%
Over the last year, the Research & Development growth was 8%. The average annual Research & Development growth rates for Surface Oncology Inc have been -12% over the past three years , -2% over the past five years .
